Pediatric / Adolescent Versions of the SDS (SDS-P) and (SDS-A)

Name: Pediatric / Adolescent Versions of the SDS (SDS-P) and (SDS-A)
SKU: 10050-2
Price: 4.00 USD
Availability: InStock

$4.00

PREVIEW ONLY, NOT A LICENSE FOR USE

To License the SDS Click Below

Purchasing a download of the SDS on this website is NOT a license agreement for use. Click here to download the license agreement.

Dr. Sheehan licenses the SDS in paper format for distribution as follows : 1) in paper format for any uses; or 2) in fixed pdf form, paper form, or both for use in clinical or academic research trials or studies.

There is a charge per individual use (not per patient enrolled). The amount must be paid in full before study initiation.

Customizable

Dr. Sheehan can design customized additional optional modules for the MINI / MINI Kid for other disorders and can customize scales to meet the needs of a specific study or clinical setting. Contact Dr. Sheehan at davidVsheehan@gmail.com to discuss a customized version designed for your needs.

Consult with Dr. Sheehan

Dr. Sheehan only provides consultation, guidance on regulatory agency questions, and training to those who license the MINI / MINI Kid or scales directly from him. Contact Dr. Sheehan at davidVsheehan@gmail.com for additional information.

Training on the SDS

For information about virtual web-based training on the SDS – which include a video, a quiz, and a certificate of completion of training – email training@harmresearch.org:

Adult Standard SDS Training

For certain sites, Dr. Sheehan can do an additional live Zoom question and answer session to address issues encountered after the raters at the site have done a dozen or so with real patients.

Please contact: davidVsheehan@gmail.com

Training video subtitles are available in multiple languages on request. Contact training@harmresearch.org for more information.

Translations and Linguistic Validation of the SDS

The non-profit Mapi Research Trust (MAPI) / ICON Language Services, in Lyon, France, is the sole translation service for existing non-English translations for all rating scales and diagnostic interviews that Dr. Sheehan licenses and distributes directly under a license from him.

Dr. Sheehan has collaborated closely with MAPI on these translations for over 15 years and continues to do so. This is to ensure the production of consistent and conceptually equivalent translations of the MINI and its variants and of Dr. Sheehan’s scales, and to be able to provide linguistic validation and certification of these translations. MAPI / Icon Language Services does not distribute the English source language version of the MINI / MINI Kid and scales, which are available from Dr. Sheehan directly.

When Dr. Sheehan fully executes your license agreement request, he will provide you with the information to contact MAPI / Icon Language Services to obtain consistent and conceptually equivalent, and linguistically validated translations and the related certificates.

MAPI / Icon Language Services may charge its own usual fees for this work.

How to Cite the SDS

The SDS has been cited over 3,000 times in publications.

Use the following citations in referencing the SDS:

Sheehan KH; Sheehan DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. International Clinical Psychopharmacology 2008;23(2):70-83. DOI: http://dx.doi.org/10.1097/YIC.0b013e3282f2b4d6
Sheehan DV, Harnett-Sheehan K, Raj BA (1996). The measurement of disability. Int Clin Psychopharmacol 11 (Suppl 3):89–95. PDF: http://journals.lww.com/intclinpsychopharm/Abstract/1996/06003/The_measurement_of_disability.15.aspx
Leon AC, Shear MK, Portera L, et al: Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 27:78–82, 1992. DOI: http://dx.doi.org/10.1007/BF00788510
Leon AC, Olfson M, Portera L, et al: Assessing impairment in primary care: a psychometric analysis of the Sheehan Disability Scale. Int J Psychiatry Med 27:93–105, 1997. DOI: http://dx.doi.org/10.2190/T8EM-C8YH-373N-1UWD
Olfson M, Kathol RG, Weissman MM, Sheehan DV, Leon AC, Hoven C. Mental Disorders and Disability in a Primary Care Group Practice. American Journal of Psychiatry. 1997; 154: 1734-1740. DOI: http://dx.doi.org/10.1176/ajp.154.12.1734
Sheehan DV, Harnett-Sheehan K. Psychometric Assessment of Anxiety Disorders. Chapter 8 in Anxiety: Psychobiological and Clinical Perspectives (Sartorius N, Andreoli V, Cassano G, Eisenberg L, Kielholz P, Pancheri P, & Racagni G, eds. Hemisphere Publishing Corporation, Washington, DC. 1990; 85-100. ISBN: 1560320648, 9781560320647.
Sheehan, D. V. (2000). Sheehan disability scale. Handbook of psychiatric measures, 113-115. ISBN: 0890424152, 9780890424155.
Sheehan DV, Meyers AL, Prakash A, Robinson MJ, Swindle RW, Russell JM, et al. The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. Current Medical Research and Opinion. 2008; 24(9):2457-66. DOI: http://dx.doi.org/10.1185/03007990802293643
Sheehan, DV, Harnett-Sheehan, K, Spann, M, Thompson, H, Prakash, A. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale. International clinical psychopharmacology. 2011;2: 75-83. DOI: http://dx.doi.org/10.1097/YIC.0b013e328341bb5f
Sheehan DV, Chokka PR, Granger RE, Walton RJ, Raskin J, Sagman D. Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine. Human Psychopharmacology: Clinical and Experimental. 2011;26(3):242-51. DOI: http://dx.doi.org/10.1002/hup.1199
Mancini, M, Sheehan DV, Demyttenaere, K, Amore, M, Deberdt, W, Quail, D, Sagman, D. Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies. International Clinical Psychopharmacology. 2012; 27(6): 298-309. DOI: http://dx.doi.org/10.1097/YIC.0b013e3283589a3f
Sheehan DV, Locklear J, Svedsäter H, Datto C. Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate. International Clinical Psychopharmacology. 2012;27(5):239-48. DOI: http://dx.doi.org/10.1097/YIC.0b013e328356ac78
Sheehan, DV, Svedsäter, H, Locklear, JC, Eriksson. Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): Data from a randomized-withdrawal, placebo-controlled maintenance study. Journal of Affective Disorders. 2013; 151(3): 906-913. DOI: http://dx.doi.org/10.1016/j.jad.2013.07.037

Description
Additional information

About the Pediatric SDS and the Adolescent SDS:

The Pediatric Sheehan Disability Scale (SDS-P) and Adolescent Sheehan Disability Scale (SDS-A) are short, simple, treatment outcome measures of disability and functional impairment. They are designed to be sensitive to change and to treatment effects in patients with psychiatric and medical disorders. The (SDS-P) is a parent- or clinician-rated version, while the SDS-A is a patient rated version by the adolescent.

About the SDS:

The Sheehan Disability Scale (SDS) is a short, simple, and cost-effective measure of disability and functional impairment that can be quickly administered and scored without disrupting the flow of routine care. The SDS is a composite of three self-rated items designed to measure the extent to which three major domains in the patient’s life are functionally impaired by psychiatric or medical symptoms. The SDS assesses functional impairment in three major life domains: work, social life/leisure activities, and family life/home responsibilities. To improve sensitivity the SDS uses a discretized analog (Discan) scaling metric to simultaneously anchor the impairment spatio-visually, numerically and verbally-descriptively. The Sheehan Disability Scale was developed as a treatment outcome measure that would be sensitive to change and to drug placebo differences over time. Its validity and reliability has been investigated in several studies (references 1, 3, 4, and 5).

Notes About this Product:

Please note: purchasing a watermarked, preview download is not a license agreement for use. Downloading a watermarked, preview copy from the website is not a license for use.

You will be allowed to download this interview twice. Any additional downloads will require additional purchase. This interview is in PDF format. You will need a PDF reader to view the interview. You can download Adobe Acrobat Reader DC here. This preview copy is in fixed PDF format.

You will have 30 days to download your preview copy. If you do not download your preview copy in 30 days, you will need to purchase a preview copy again.

Please note that the product you receive may differ from the images shown in this preview of the product.

Product Type	Sheehan Scales, Disability / Impairment Scales
Screen or Track	Tracking Outcomes
Population Age	Child / Pediatric
Study Type	ADHD, Addictive Disorder, Anxiety Disorder, Bipolar Disorder, CNS, Conduct Disorder, Disruptive Disorder, Eating Disorder, Feeding Disorder, Homicidality, Impulse-Control Disorder, MDD, Neurodevelopmental Disorder, OCD, Personality Disorder, Psychotic Disorder, PTSD, Schizophrenia Spectrum Disorder, Stressor-Related Disorder, Substance-Related Disorder, Substance Use Disorder, Suicidality (Disorder), Trauma-Related Disorder

Pediatric / Adolescent Versions of the SDS (SDS-P) and (SDS-A)

You may also like…

Related products

Login

Register